Halozyme Therapeutics (HALO) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to -$142.8 million.
- Halozyme Therapeutics' Enterprise Value rose 7603.99% to -$142.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$142.8 million, marking a year-over-year increase of 7603.99%. This contributed to the annual value of -$142.8 million for FY2025, which is 7603.99% up from last year.
- Latest data reveals that Halozyme Therapeutics reported Enterprise Value of -$142.8 million as of Q4 2025, which was up 7603.99% from -$702.0 million recorded in Q3 2025.
- Halozyme Therapeutics' 5-year Enterprise Value high stood at -$142.8 million for Q4 2025, and its period low was -$815.9 million during Q3 2021.
- Moreover, its 5-year median value for Enterprise Value was -$538.6 million (2024), whereas its average is -$527.0 million.
- As far as peak fluctuations go, Halozyme Therapeutics' Enterprise Value crashed by 13533.48% in 2021, and later skyrocketed by 7603.99% in 2025.
- Quarter analysis of 5 years shows Halozyme Therapeutics' Enterprise Value stood at -$740.9 million in 2021, then skyrocketed by 51.03% to -$362.8 million in 2022, then rose by 7.39% to -$336.0 million in 2023, then tumbled by 77.4% to -$596.1 million in 2024, then soared by 76.04% to -$142.8 million in 2025.
- Its Enterprise Value was -$142.8 million in Q4 2025, compared to -$702.0 million in Q3 2025 and -$548.2 million in Q2 2025.